Myopia

The expansion includes community health centers in the greater Boston area and Rhode Island.

The 0.1 mg/mL atropine eye drop for pediatric myopia is licensed from Sydnexis, Inc.

An official approval by the FDA in the United States can boost adoption rate of atropine and antimyopia glasses, which will change the landscape of myopia management.

IVMED-85 is a preservative-free, nonatropine daily drop that slows myopia progression by strengthening scleral and corneal collagen crosslinks via LOX activation.

Increases in the doses of atropine were most common following the pandemic and especially among patients for whom therapy was initiated with the 0.01% dose.

New data from North American and Chinese clinical trials reinforce the safety, efficacy, and durability of DOT lenses in slowing pediatric myopia progression, without evidence of rebound.

After treatment cessation, eye growth returned to age-expected levels and the accumulated myopia control treatment gains were retained over the following 12 months after treatment was ceased.

The CATHAY trial evaluated 186 myopic children, 6 to 13 years old at initiation, across 5 hospitals.

Researchers found that repeated therapy using low-level red light (RLRL) is a potential intervention to control myopia progression in children.

According to a press release, Myatro XL is the first 0.05% atropine eye drop for pediatric myopia control. It will be commercially available in India in July 2025.

How studies into myopia management can increase access to vision care.

A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary end point for slowing pediatric myopia progression.

Paul Karpecki, OD, FAAO, sits down to discuss Sydnexis's atropine formulation and what an FDA approval would mean for myopia management.

In April 2021, WCO partnered with CooperVision to introduce its myopia management standard of care, defining evidence-based standard of care comprising of mitigation, measurement, and management.

The 6th World Congress of Optometry will be held during Saudi Society of Optometry’s 11th Optometry Conference and Exhibition.

The system aids in the orthokeratology lens design process by syncing directly with topographers to create precise lens designs for the treatment of myopia in the matter of seconds.

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.

Ashley Wallace Tucker, OD, FAAO, FSLS, Dipl ABO, weighs in on what's on the horizon for pediatric myopia management, and provides some tips for diving into scleral lens fitting.

The upgraded Myopia Software Package offers comprehensive screening, ortho-k fitting, and myopia management in one device.

The study evaluated 13 teenagers and young adults who had high myopia (−6.50 to −9.25 D).

At the Envision Summit 2025 in San Juan, Puerto Rico, Ashley Wallace Tucker, OD, FAAO, FSLS, gave insight into advancements in keratoconus management and the importance of early detection as well as tips and advice on fitting scleral contact lens

Walline, OD, PhD, FAAO, outlines how to predict myopia progression and delay its onset in an exclusive interview with Optometry Times.

Jeffrey Walline, OD, PhD, FAAO, overviews a presentation he gave on the Bifocal Lenses in Nearsighted Kids 2 (BLINK2) cohort study at the Collaborative Community on Ophthalmic Innovation (CCOI).

Visual acuity remains an important indication of ocular and visual health.

The 2025 Myopia Research Grant will comprise of 3 awards of $500,000 each.

From eye drops to novel treatments, it’s time to assess all options for improving patients’ visual acuity.

The updated range of lenses feature expanded negative and cylindrical powers, thinner edge thickness, and wider frame options.

The longitudinal study found that visual function and BCVA decreased with an increasing incidence rate of moderate and severe visual impairment for patients with high myopia.